JP2019521964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521964A5 JP2019521964A5 JP2018559812A JP2018559812A JP2019521964A5 JP 2019521964 A5 JP2019521964 A5 JP 2019521964A5 JP 2018559812 A JP2018559812 A JP 2018559812A JP 2018559812 A JP2018559812 A JP 2018559812A JP 2019521964 A5 JP2019521964 A5 JP 2019521964A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- unsubstituted
- compound
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 24
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 21
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims description 2
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 2
- DXPOSRCHIDYWHW-UHFFFAOYSA-N Xamoterol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1 DXPOSRCHIDYWHW-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000001800 adrenalinergic effect Effects 0.000 claims description 2
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 claims description 2
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 claims description 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000035790 physiological processes and functions Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 208000037816 tissue injury Diseases 0.000 claims description 2
- 229960004928 xamoterol Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- -1 C1-C5 alkyl linker compound Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 230000037361 pathway Effects 0.000 description 3
- 102000000072 beta-Arrestins Human genes 0.000 description 1
- 108010080367 beta-Arrestins Proteins 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662336370P | 2016-05-13 | 2016-05-13 | |
| US62/336,370 | 2016-05-13 | ||
| PCT/US2017/032505 WO2017197324A1 (en) | 2016-05-13 | 2017-05-12 | Adrenergic receptor modulating compounds and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521964A JP2019521964A (ja) | 2019-08-08 |
| JP2019521964A5 true JP2019521964A5 (enExample) | 2020-05-21 |
Family
ID=60267581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559812A Pending JP2019521964A (ja) | 2016-05-13 | 2017-05-12 | アドレナリン受容体調節化合物およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11173144B2 (enExample) |
| EP (1) | EP3454845A4 (enExample) |
| JP (1) | JP2019521964A (enExample) |
| KR (1) | KR20190017795A (enExample) |
| CN (1) | CN109310651A (enExample) |
| AU (1) | AU2017263657A1 (enExample) |
| BR (1) | BR112018073227A2 (enExample) |
| CA (1) | CA3023763A1 (enExample) |
| MA (1) | MA44994A (enExample) |
| MX (1) | MX2018013812A (enExample) |
| WO (1) | WO2017197324A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405091A1 (en) | 2019-12-18 | 2022-07-14 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| EP4161496A4 (en) * | 2020-06-04 | 2024-08-21 | Curasen Therapeutics, Inc. | FORMS AND COMPOSITIONS OF A BETA-ADRENERGIC AGONIST |
| US20240352002A1 (en) * | 2020-11-19 | 2024-10-24 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
| WO2023192319A1 (en) * | 2022-03-28 | 2023-10-05 | University Of South Florida | Chemokine receptors and alpha1 adrenergic receptors/vasopressin receptors 1a heteromers as drug targets for disease |
| GB202213163D0 (en) * | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| CN115414483B (zh) | 2022-09-26 | 2024-10-29 | 孙良丹 | Adrb1活性抑制剂在作为或制备用于治疗银屑病的制剂中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2619164C2 (de) * | 1976-04-30 | 1985-07-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Indazolyl-(4)-oxy-propanolamine, Verfahren zu ihrer Herstellung und deren Verwendung |
| DE2830211A1 (de) * | 1977-07-21 | 1979-02-01 | Sandoz Ag | Substituierte indol-derivate, ihre herstellung und verwendung |
| DE2905877A1 (de) * | 1979-02-16 | 1980-08-28 | Boehringer Mannheim Gmbh | Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DD150456A5 (de) * | 1979-03-01 | 1981-09-02 | Ciba Geigy Ag | Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols |
| DE3023369A1 (de) | 1980-06-23 | 1982-01-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5098996A (en) * | 1984-10-26 | 1992-03-24 | The United States Of America As Represented By The Department Of Health And Human Services | Process for introducing fluorine into biologically active materials |
| JPH09510964A (ja) * | 1994-01-29 | 1997-11-04 | 藤沢薬品工業株式会社 | 抗高血圧剤としての４−（２−（３−アリールオキシ−２−ヒドロキシプロピルアミノアルキルオキシ）−５−ニトロフェニル）−１，４−ジヒドロピリジン |
| AU6050000A (en) * | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| EP1328261A2 (en) * | 2000-04-12 | 2003-07-23 | Minerva Biotechnologies Corporation | Treatment of neurodegenerative disease |
| JP2004534772A (ja) * | 2001-05-24 | 2004-11-18 | 藤沢薬品工業株式会社 | アミノアルコール誘導体 |
| DK1492519T3 (da) * | 2003-03-21 | 2007-03-05 | Dynogen Pharmaceuticals Inc | Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer |
| EP1833480A2 (en) * | 2004-11-30 | 2007-09-19 | Artesian Therapeutics, Inc. | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| US20100216805A1 (en) * | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9072746B2 (en) * | 2010-04-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| US9849134B2 (en) * | 2014-02-18 | 2017-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and social behavior in humans having deficits therein due to neurodegenerative disorders and compounds and compositions therefor |
-
2017
- 2017-05-12 KR KR1020187036246A patent/KR20190017795A/ko not_active Withdrawn
- 2017-05-12 MA MA044994A patent/MA44994A/fr unknown
- 2017-05-12 WO PCT/US2017/032505 patent/WO2017197324A1/en not_active Ceased
- 2017-05-12 MX MX2018013812A patent/MX2018013812A/es unknown
- 2017-05-12 CA CA3023763A patent/CA3023763A1/en not_active Abandoned
- 2017-05-12 JP JP2018559812A patent/JP2019521964A/ja active Pending
- 2017-05-12 CN CN201780038617.4A patent/CN109310651A/zh active Pending
- 2017-05-12 EP EP17796976.3A patent/EP3454845A4/en not_active Withdrawn
- 2017-05-12 AU AU2017263657A patent/AU2017263657A1/en not_active Abandoned
- 2017-05-12 BR BR112018073227-3A patent/BR112018073227A2/pt not_active Application Discontinuation
- 2017-05-12 US US16/099,802 patent/US11173144B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521964A5 (enExample) | ||
| JP6964450B2 (ja) | 造影剤の合成および使用のための組成物、方法およびシステム | |
| JP7335241B2 (ja) | 統合的ストレス経路の調節剤 | |
| JP7203964B2 (ja) | 統合的ストレス経路のプロドラッグ調節剤 | |
| JP6342805B2 (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| JP7307057B2 (ja) | 統合的ストレス経路の調節剤 | |
| CN107108671B (zh) | 作为raf激酶抑制剂的化合物和组合物 | |
| JP7390415B2 (ja) | ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用 | |
| ES2243441T3 (es) | Derivados de imidazolio fundidos. | |
| JP2019512009A (ja) | スルホニルウレアおよび関連化合物ならびにこれらの利用 | |
| CN101945876B (zh) | 对慢性疼痛疾病有活性的含氮双环化合物 | |
| WO2017180769A1 (en) | Small molecules for immunogenic treatment of cancer | |
| CN105085482B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| US20230339867A1 (en) | Pyrazine compounds as inhibitors of flt3 | |
| JP2018511627A (ja) | Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用 | |
| CA3009324A1 (en) | Cortistatin analogs and uses thereof | |
| EP3700891A1 (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke | |
| JP6100755B2 (ja) | （２−ヘテロアリールアミノ）コハク酸誘導体 | |
| TW202406902A (zh) | 趨化介素受體調節劑及其用途 | |
| JP2022520907A (ja) | Ｎｕｒｒ１受容体調節因子 | |
| JP2008543828A (ja) | ドーパミン作動薬としての３−フェニルアゼチジン誘導体 | |
| JP6386541B2 (ja) | プロムネシア効果を有するアセチルコリンエステラーゼ抑制化合物と５ｈｔ４セロトニン作動性受容体作動薬の調製方法並びにその構成薬剤組成 | |
| JP5864046B2 (ja) | １１ｃ標識イソキノリン誘導体、その製造方法、その前駆体、それを利用したｐｅｔ用プローブ及び組織の画像化方法 | |
| JP2025535057A (ja) | フェニルオキシアミドキナーゼ阻害剤 | |
| JP2013521316A5 (enExample) |